On paper this isn't close. Turkey tail has a meta-analysis of 13 randomised trials showing a 9% absolute reduction in five-year mortality — one additional patient alive for every eleven treated. Reishi has a Cochrane review that found nothing on its metabolic endpoints. Then you check what was actually swallowed in each case, and the ranking stops being useful. One mushroom has strong evidence for a material you cannot buy. The other has weak evidence for something close to what's on the shelf.
Trametes Versicolor's evidence is the strongest in the category and the least transferable: Eliza's 2012 meta-analysis of 13 trials found a 9% absolute reduction in five-year mortality (number needed to treat 11), and Nakazato's 1994 Lancet trial in 262 gastric cancer patients reported five-year survival of 73.0% against 60.0% (p = 0.044) — all using purified PSK alongside chemotherapy for one to three years. Reishi's trials used consumer-scale doses of 1.4–5.4 g/day but measured soft endpoints: fatigue fell 28.3% against 20.1% on placebo in 132 patients (Tang 2005), while a Cochrane review of five trials found no effect on HbA1c, cholesterol or BMI.
So the question isn't which mushroom is better. It's whether you want the better evidence or the more applicable evidence, because they point at different products.
How Strong Is Turkey Tail's Evidence, Really?
Stronger than anything else in functional mushrooms. Eliza's 2012 systematic review and meta-analysis pooled 13 randomised, placebo-controlled, double-blind trials of Yun Zhi — the Chinese preparation of Coriolus versicolor, now called Trametes versicolor. Patients randomised to it had a 9% absolute reduction in five-year mortality.
Translated into the number clinicians use: treat eleven patients and one additional person is alive at five years. The effect was clearest in breast, gastric and colorectal cancer, and absent in oesophageal and nasopharyngeal.
Nakazato's earlier Lancet trial is the anchor study inside that literature: 262 patients after curative gastrectomy, randomised to standard adjuvant chemotherapy with or without PSK, five-year survival 73.0% against 60.0% (p = 0.044) and disease-free survival 70.7% against 59.4% (p = 0.047).
Why Doesn't That Answer the Question You're Asking?
Three reasons, and each one on its own would be enough.
The material is wrong. PSK is a purified protein-bound polysaccharide manufactured to pharmaceutical specification and licensed in Japan since 1977. It is not turkey tail tea, powder or tincture. Our dosage guide works through how far a consumer extract falls short of the trial figure.
The population is wrong. Every survival trial recruited cancer patients receiving cytotoxic chemotherapy. Nothing in that dataset speaks to immune function in a healthy adult who wants to catch fewer colds.
The schedule is wrong. PSK was given at 3 grams a day for one to three years, under oncology supervision, as an adjunct to treatment. That's a medical protocol, not a supplement habit.
What Does Reishi Have Instead?
Weaker findings on more relevant products. Tang's 2005 trial randomised 132 patients with neurasthenia to Ganopoly at 1,800 mg three times daily — 5.4 grams a day — or placebo for eight weeks. Fatigue fell 28.3% from baseline against 20.1% on placebo, and 51.6% of the reishi group were rated more than minimally improved against 24.6% (p = 0.002).
On immune parameters specifically, Gao's 2003 study gave 34 advanced-stage cancer patients the same 1,800 mg three times daily for 12 weeks and compared cytokines, T-cell subsets, mitogen response and NK activity against baseline. No control group, so it's a before-and-after rather than a trial.
And the counterweight: Klupp's 2015 Cochrane review of five trials and 398 participants found Ganoderma lucidum at 1.4 to 3 g/day produced no significant change in HbA1c, total cholesterol, LDL or BMI. Reishi has been tested and found wanting on hard biochemical endpoints.
Do They Even Work the Same Way?
No, and the mechanisms are genuinely different rather than differently branded. Trametes' active fractions are protein-bound polysaccharides — PSK and PSP — which act as immunomodulators and were developed as pharmaceuticals for that purpose. Our PSK and PSP article covers the mechanism.
Reishi brings two fractions: water-soluble beta-glucans and alcohol-soluble triterpenes. Only the polysaccharide fraction has ever been in a positive human trial, which is awkward for the dual-extraction marketing, as our reishi format guide explains.
Side by Side
| Turkey tail (Trametes) | Reishi | |
|---|---|---|
| Best result | 9% absolute drop in 5-year mortality, NNT 11, across 13 RCTs | Fatigue −28.3% vs −20.1%; 51.6% vs 24.6% improved |
| Material tested | Purified PSK / PSP, a licensed drug | Polysaccharide extract at consumer-scale doses |
| Population | Cancer patients on chemotherapy | Outpatients with neurasthenia; cancer patients for immune markers |
| Dose and duration | 3 g/day for 1–3 years, supervised | 1.4–5.4 g/day for 8–16 weeks |
| Where it failed | Oesophageal and nasopharyngeal cancer | HbA1c, cholesterol, LDL, BMI — all null in Cochrane |
| Immune endpoint in healthy people | Never tested | Never tested |
| Dose-ranging safety data | Yes — 3, 6 and 9 g/day, no MTD reached | No formal escalation study |
Which Has Better Safety Data?
Turkey tail, and it's not a close call either. Torkelson's phase I escalation gave women recovering from breast-cancer radiotherapy 3, 6 or 9 grams a day for six weeks. Eleven were recruited, nine completed, nine adverse events were recorded in total — seven mild, one moderate, one severe — and no maximum tolerated dose was reached at 9 grams.
Reishi has no equivalent escalation study. Its known cautions are an antiplatelet effect that matters if you take anticoagulants or have surgery scheduled, plus mild GI effects. Both species' profiles are covered in our turkey tail and reishi safety articles.
So Which Should You Buy?
- If you're in cancer treatment, this isn't a shopping decision. The Trametes evidence exists inside supervised oncology, and that conversation belongs with your oncologist — see our oncology support article for the framing, not for advice.
- If you want the mushroom whose trials resemble what you'd actually take, buy reishi. Tang's participants took a dose you can reach.
- If fatigue or sleep is the real complaint, reishi again. That's the endpoint that actually moved.
- If you want turkey tail anyway, buy it as a drink and don't expect the trial numbers. The tea versus extract comparison covers what you're getting.
- If your goal is general immune support in a healthy body, neither has evidence for that. Shiitake at food doses is the only thing in the category tested in healthy adults, per our immunity ranking.
The Honest Verdict
Turkey tail wins on evidence quality and loses on relevance. Reishi wins on relevance and loses on evidence quality. For a healthy adult buying either one for "immune support", the comparison has no winner — because the question has never been studied in that population with either mushroom.
That's an unsatisfying answer, and it's the accurate one. Anyone giving you a confident ranking here is filling the same gap with something other than data.
Frequently Asked Questions
Is turkey tail better than reishi for immunity?
It has far better evidence — 13 randomised trials showing a 9% absolute reduction in five-year mortality — but all of it used purified PSK as a drug alongside chemotherapy. Neither mushroom has been tested for immune outcomes in healthy adults.
Can I take turkey tail and reishi together?
No interaction between them is documented. The practical objection is that stacking makes attribution impossible, and blends deliver a fraction of each species — rarely near the 3 g PSK or 5.4 g reishi figures the trials used.
How much turkey tail should I take?
Trials used 3 grams a day of purified PSK, and a phase I found 9 grams tolerable with no maximum dose reached. A consumer extract at 3 grams delivers substantially less polysaccharide than the pharmaceutical did, so the number doesn't transfer directly.
Does reishi actually do anything measurable?
Yes, on subjective endpoints. In 132 patients, fatigue fell 28.3% against 20.1% on placebo and the responder rate was 51.6% against 24.6% (p = 0.002). On HbA1c, cholesterol, LDL and BMI, a Cochrane review of five trials found nothing.
Which one is safer?
Turkey tail has better safety documentation, with a formal escalation to 9 grams a day producing nine adverse events across the study and no maximum tolerated dose. Reishi has no escalation study but a known antiplatelet caution relevant to anticoagulants and surgery.
Shop Turkey Tail and Reishi
Dried Trametes Versicolor (100 g €29, 300 g €69, 500 g €89) is the cheapest way to drink it, and Trametes tincture (50 ml €49, 100 ml €79) the most concentrated. Reishi capsules (120 caps €39, 2 × 120 €70) and dried reishi (100 g €49, 1 kg €349) cover the species with the more applicable trials. The immunity collection holds both. Free shipping on orders over €50.
Related Articles
- Trametes Versicolor: PSK, PSP and Immune Modulation
- Trametes Versicolor in Adjunct Oncology
- Turkey Tail Dosage Guide
- Reishi Dosage Guide
- Reishi vs Chaga
- Best Mushrooms for Immunity
- Turkey Tail Timing Guide
Sources
- Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Pat Inflamm Allergy Drug Discov. 2012;6(1):78-87. PubMed 22185453
- Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994;343(8906):1122-1126. PubMed 7910230
- Torkelson CJ, Sweet E, Martzen MR, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632. PubMed 22701186
- Tang W, Gao Y, Chen G, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8(1):53-58. PubMed 15857210
- Klupp NL, Chang D, Hawke F, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev. 2015;(2):CD007259. PubMed 25686270
- Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest. 2003;32(3):201-215. PubMed 12916709